SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) today announced that Vical's President and Chief Executive Officer,
Vijay B. Samant, will provide an overview of the company's technologies,
development programs, and strategic partnerships at three upcoming investor
* Bank of America 2008 Health Care Conference (Las Vegas, May 13 - 15),
* FBR Capital Markets 12th Annual Spring Investor Conference
(New York, May 28-29),
* Needham & Company Seventh Annual Biotechnology and Medical Technology
A webcast of the presentation at the Needham conference will be available live and archived through the events page at http://www.vical.com.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks
|SOURCE Vical Incorporated|
Copyright©2008 PR Newswire.
All rights reserved